222 related articles for article (PubMed ID: 20164585)
21. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Mecocci P; Bladström A; Stender K
Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
[TBL] [Abstract][Full Text] [Related]
22. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
Erkinjuntti T; Skoog I; Lane R; Andrews C
Int J Clin Pract; 2003 Nov; 57(9):756-60. PubMed ID: 14686563
[TBL] [Abstract][Full Text] [Related]
23. Long-term rivastigmine treatment in a routine clinical setting.
Minthon L; Wallin AK; Eriksson S; Wattmo C; Andreasen N
Acta Neurol Scand; 2009 Mar; 119(3):180-5. PubMed ID: 18759798
[TBL] [Abstract][Full Text] [Related]
24. Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies.
McKeith IG; Wesnes KA; Perry E; Ferrara R
Dement Geriatr Cogn Disord; 2004; 18(1):94-100. PubMed ID: 15087584
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis.
Farlow MR; Small GW; Quarg P; Krause A
Dement Geriatr Cogn Disord; 2005; 20(2-3):192-7. PubMed ID: 16088144
[TBL] [Abstract][Full Text] [Related]
26. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences.
Emre M; Cummings JL; Lane RM
J Alzheimers Dis; 2007 Jul; 11(4):509-19. PubMed ID: 17656830
[TBL] [Abstract][Full Text] [Related]
27. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.
Feldman HH; Lane R;
J Neurol Neurosurg Psychiatry; 2007 Oct; 78(10):1056-63. PubMed ID: 17353259
[TBL] [Abstract][Full Text] [Related]
28. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
Visser PJ; Scheltens P; Pelgrim E; Verhey FR;
Dement Geriatr Cogn Disord; 2005; 19(2-3):126-33. PubMed ID: 15627759
[TBL] [Abstract][Full Text] [Related]
29. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
Cummings JL; Koumaras B; Chen M; Mirski D;
Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
[TBL] [Abstract][Full Text] [Related]
30. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
[TBL] [Abstract][Full Text] [Related]
31. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease.
Farlow MR; Grossberg G; Gauthier S; Meng X; Olin JT
Curr Med Res Opin; 2010 Oct; 26(10):2441-7. PubMed ID: 20828359
[TBL] [Abstract][Full Text] [Related]
32. Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study.
Simioni S; Cavassini M; Annoni JM; Métral M; Iglesias K; Rimbault Abraham A; Jilek S; Calmy A; Müller H; Fayet-Mello A; Giacobini E; Hirschel B; Du Pasquier RA
Neurology; 2013 Feb; 80(6):553-60. PubMed ID: 23345635
[TBL] [Abstract][Full Text] [Related]
33. Disease stage in Alzheimer disease and treatment effects of rivastigmine.
Kurz A; Farlow M; Quarg P; Spiegel R
Alzheimer Dis Assoc Disord; 2004; 18(3):123-8. PubMed ID: 15494617
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses.
Alva G; Grossberg GT; Schmitt FA; Meng X; Olin JT
Int J Geriatr Psychiatry; 2011 Apr; 26(4):356-63. PubMed ID: 21312297
[TBL] [Abstract][Full Text] [Related]
35. Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living.
Olin JT; Aarsland D; Meng X
Dement Geriatr Cogn Disord; 2010; 29(6):510-5. PubMed ID: 20523050
[TBL] [Abstract][Full Text] [Related]
36. Long-term efficacy and safety of celecoxib in Alzheimer's disease.
Soininen H; West C; Robbins J; Niculescu L
Dement Geriatr Cogn Disord; 2007; 23(1):8-21. PubMed ID: 17068392
[TBL] [Abstract][Full Text] [Related]
37. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial.
Mowla A; Mosavinasab M; Haghshenas H; Borhani Haghighi A
J Clin Psychopharmacol; 2007 Oct; 27(5):484-7. PubMed ID: 17873681
[TBL] [Abstract][Full Text] [Related]
38. Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.
Weintraub D; Somogyi M; Meng X
Am J Alzheimers Dis Other Demen; 2011 Sep; 26(6):443-9. PubMed ID: 22009228
[TBL] [Abstract][Full Text] [Related]
39. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease.
Farlow MR; Cummings JL; Olin JT; Meng X
Am J Alzheimers Dis Other Demen; 2010 Jun; 25(4):347-52. PubMed ID: 20392862
[TBL] [Abstract][Full Text] [Related]
40. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial.
Ballard C; Margallo-Lana M; Juszczak E; Douglas S; Swann A; Thomas A; O'Brien J; Everratt A; Sadler S; Maddison C; Lee L; Bannister C; Elvish R; Jacoby R
BMJ; 2005 Apr; 330(7496):874. PubMed ID: 15722369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]